Related Experiment Videos
Radionuclide imaging in primary amyloidosis with liver involvement
1Department of Nuclear Medicine, Taichung Veterans General Hospital, Taiwan, Republic of China.
Clinical Nuclear Medicine
|June 10, 1998
Summary
Primary amyloidosis can affect the liver, causing hepatomegaly. Technetium-99m pyrophosphate scintigraphy offers a noninvasive method to assess liver involvement in primary amyloidosis.
Area of Science:
- Nuclear medicine imaging
- Diagnostic radiology
- Gastroenterology
Background:
- Primary amyloidosis is a systemic disease characterized by amyloid protein deposition in organs.
- Liver involvement in primary amyloidosis can lead to hepatomegaly and other clinical manifestations.
- Accurate assessment of organ involvement is crucial for patient management.
Observation:
- A 74-year-old male patient presented with hepatomegaly, hyperglycemia, and proteinuria.
- Liver biopsy confirmed primary amyloidosis with liver involvement.
- Tc-99m phytate liver-spleen imaging showed abnormal tracer distribution in the liver.
- Tc-99m pyrophosphate whole body imaging revealed abnormal tracer uptake by the liver.
Findings:
- Scintigraphic imaging, specifically Tc-99m pyrophosphate scans, demonstrated abnormal liver uptake in a patient with primary amyloidosis.
- These findings suggest that nuclear imaging can detect amyloid deposition in the liver.
- The imaging results correlated with biopsy-proven liver involvement.
Implications:
- Scintigraphic imaging may serve as a noninvasive tool for evaluating liver involvement in primary amyloidosis.
- Utilizing imaging techniques can potentially reduce the need for invasive procedures like liver biopsy.
- This approach may lower the risk of complications, such as bleeding, associated with biopsies.